Preclinical Drug Discovery & Toxicology

Facilitates target discovery and validation

The AQUA® platform provides unprecedented information about protein expression in tissue to advance personalized medicine. AQUA enables researchers  to discover & validate new drug targets, accelerate clinical development of safer & more effective targeted biotherapies.

  • Discover new protein biomarkers for disease detection, diagnosis, and treatment
  • Identify potential new drug targets
  • Monitor preclinical drug efficacy
  • Develop & validate novel diagnostic reagents and tests corresponding to new biospecific therapeutics
  • Validate animal models for similarities in protein pathways of human disease

Partial list of validated assays performed by HistoRx using AQUA® analysis

  • pAkt
  • E-Cadherin
  • C-met
  • CREB
  • pCREB
  • EGFR VIII
  • ERCC-1
  • ER
  • PR
  • EGFR
  • EGFR VIII
  • HER2
  • HER3
  • IGF1R
  • FAK
  • GSK3β
  • pGSK3β
  • Integrin Alpha V
  • Integrin Beta 1
  • Integrin Beta 3
  • Integrin Beta 5
  • Integrin Beta 6
  • mTOR
  • pmTOR
  • pMAPK
  • pNF-kB p65
  • p130cas
  • phospho-p70 S6 kinase
  • pSMAD2
  • pH3
  • Paxillin
  • PTEN Src pSRC
  • Thymidylate Synthase
  • Vimentin